Xbrane Biopharma AB (OSTO:XBRANE) Change In Payables And Accrued Expense : kr0.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Xbrane Biopharma AB Change In Payables And Accrued Expense?

Xbrane Biopharma AB's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was kr0.0 Mil. It means Xbrane Biopharma AB's Accounts Payable & Accrued Expense stayed the same from Sep. 2023 to Dec. 2023 .

Xbrane Biopharma AB's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was kr0.0 Mil. It means Xbrane Biopharma AB's Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Dec. 2023 .

Xbrane Biopharma AB Change In Payables And Accrued Expense Historical Data

The historical data trend for Xbrane Biopharma AB's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xbrane Biopharma AB Change In Payables And Accrued Expense Chart

Xbrane Biopharma AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

Xbrane Biopharma AB Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Xbrane Biopharma AB Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.0 Mil.

Xbrane Biopharma AB Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Xbrane Biopharma AB's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Xbrane Biopharma AB (OSTO:XBRANE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (OSTO:XBRANE) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

7XB:Germany

Address

Retzius vag 8, Solna, SWE, 171 65

Website

https://www.xbrane.com

Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company has a patented protein production platform with up to 12 times greater productivity than standard systems for the production of proteins in E.coli host cells. Xbrane's leading product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. The company's geographical segments include the Middle East, Asia, Europe, and the United States.

Xbrane Biopharma AB (OSTO:XBRANE) Headlines

No Headlines